Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Abbott Labs

Teladoc

Want to play it safe in a volatile market? Go for these three top-notch healthcare picks.

3 Top Healthcare Stocks to Buy in February

Bear of the Day: CRISPR Therapeutics (CRSP)

Clough Global Opportunities Fund

Clough Global Equity Fund

Clough Global Dividend and Income Fund

PennyMac Financial Services

The Clough funds all have impressive records. GLV previously paid a higher distribution yield even though it didn't earn as much as its two siblings, GLO and GLQ. That's been rectified with the big dividend increases (21%) for GLO and GLQ and the slight (4%) cut to GLV's payout.

The Clough Closed-End Funds Continue To Perform

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Editas Medicine

Which of these two hot gene therapy stocks is the better buy?

Better Buy: CRISPR Therapeutics vs. Editas Medicine

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer. Mr. Drouet brings more than 20 years of leadership experience in global pharmaceutical marketing and joins CRISPR Therapeutics to develop and oversee the Company's global commercialization efforts.

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

CRISPR Therapeutics stock, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has plunged by 14% over the last 10 trading days, and it is down 10% over the last 5 trading days. Earlier this month, CRSP stock made its lifetime high of $210, and it.

What's Next For CRISPR Stock After A 14% Fall?

Corcept Therapeutics

Fate Therapeutics

Jounce Therapeutics

Lexicon Pharmaceuticals

Time will always be on the investor's side.

Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now

Fulgent Genetics

Invitae

Genetic testing companies have to appeal to several stakeholders in the healthcare system in order to make it to the next level.

Here's How the Genetic Testing Industry Can Get Even Bigger

Johnson & Johnson

SPDR S&P 500 ETF Trust

Vertex Pharmaceuticals

Vanguard Total Stock Market ETF

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Where to Invest $1 Million Right Now

Beam Therapeutics

Intellia Therapeutics

SpringWorks Therapeutics Inc

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors might want to track the progress of those still-private firms in the event they take the initial public offering route down the line.

Beam, SpringWorks Biggest Gainers on BioSpace List

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why

These companies offer some of the most innovative technologies in the life sciences industry.

2 Biotech Stocks That Could Double Your Money

Cellectis SA

Calyxt

Sangamo Therapeutics

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

7 CRISPR Stocks for the Future of Medicine

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible for a medical condition with healthy versions.

CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla

Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The post Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs appeared first on Investor's Business Daily.

Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

3 Biotech Technological Developments to Watch Out For in 2021

ARK Fintech Innovation ETF

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

ARK Web x.0 ETF

Roku

Block

Tesla

Berkshire's best days seem to be behind it, but this investing wiz could be the next Buffett.

Move Over, Warren Buffett: This Is the Star Investor You Should Be Following

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today

Since the Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for their work on gene editing technology, CRISPR, related stocks have been red hot. CRISPR technology promises to make what was merely a subject of sci-fi into reality, and will completely revolutionize the way we approach medicine.

CRISPR Is The Future Of Medicine, And CRSP Is One Stock To Own

Denali Therapeutics

Seres Therapeutics

NantKwest

Rocket Pharma

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

5 Medical Outperformers That Might Lose Steam in 2021

CRSP stock is rallying today as CRISPR Therapeutics and its gene-editing peers move into the spotlight. Here's what you should know.

CRSP Stock: Why CRISPR Therapeutics Shares Are Climbing Today

Alexion Pharma

Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.

3 Biotech Stocks That Could Explode Higher in 2021

News for CRISPR Therapeutics Stock (CRSP)